Two GLP-1 Drugs Finally Went Head to Head on Heart Attacks. It Was a Tie.

On August 28, 2026, the FDA approved tirzepatide, sold as Mounjaro, to lower the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk of them. That means cardiovascular death, non-fatal heart attack, and non-fatal stroke.

This is a different kind of approval from the ones that usually make headlines in this field. It is not about weight, and it is not about blood sugar numbers. It is about whether people have fewer heart attacks, which is the outcome that actually matters.

The trial did something new

SURPASS-CVOT enrolled 13,299 adults with type 2 diabetes and established cardiovascular disease, across 640 sites in 30 countries, and followed them for a median of about four years.

The important design choice is the comparison group. Participants were not given a placebo. They received dulaglutide, sold as Trulicity, another GLP-1 drug that already had proven cardiovascular benefit.

That makes this the first cardiovascular outcomes trial to test two incretin drugs directly against each other rather than each against a dummy injection.

Why not use a placebo

Once a class of drug is known to reduce heart attacks, giving high-risk patients a placebo for four years becomes hard to justify. You would be withholding a treatment you already believe works from people with established heart disease.

Running against an active comparator solves the ethical problem and answers a more useful question. Doctors choosing between two drugs do not want to know that each beats nothing. They want to know how they compare with each other.

We have made this point before about weight loss numbers, in our piece on the amylin pipeline: results from separate trials cannot be lined up as if they were a league table. Head to head is the only comparison that settles anything. This trial is what that looks like when someone actually does it.

What the result was

Tirzepatide met its goal of non-inferiority, meaning it was not worse than dulaglutide. The rate of major cardiovascular events was about 8 percent lower, with a hazard ratio of 0.92.

The confidence interval ran from 0.83 to 1.01, and because it crosses 1.00, superiority was not established. In plain terms, the data are consistent with tirzepatide being modestly better, and also consistent with it being very slightly worse. The trial cannot tell those apart.

So the honest summary is a tie, with a hint in tirzepatide's favor that did not reach the bar for a claim.

Why a tie is still worth something

A drug that matches an established cardiovascular treatment while also being considerably more effective for weight and blood sugar is a meaningful clinical option. For a patient with type 2 diabetes and heart disease, the question is rarely which drug is best in the abstract. It is which single drug handles the most problems at once.

It also continues a pattern worth watching. These drugs keep being approved for the complications of metabolic disease rather than for the metabolic numbers themselves: sleep apnea, fatty liver disease, and the knee osteoarthritis result we covered when retatrutide reported TRIUMPH-4. The category is quietly turning into a set of treatments for the conditions obesity and diabetes drive.

What it does not mean

The approval covers adults with type 2 diabetes at high cardiovascular risk. It is not a finding about healthy people, and it is not a reason for anyone without diabetes and established heart disease to expect a cardiac benefit.

Side effects were what the class is known for, mostly gastrointestinal, generally mild to moderate, and worst while the dose is being increased.

And as always, this describes the approved medicine, prescribed and supervised. It says nothing about the versions sold outside that system, where testing has repeatedly found products that are not what their labels claim.

Source: Eli Lilly announcement of the FDA approval and SURPASS-CVOT results.